Related Experiment Video
Updated: Jun 12, 2026

Pulse Wave Velocity Testing in the Baltimore Longitudinal Study of Aging
Published on: February 7, 2014
Effects of long-term treatment for obstructive sleep apnea on pulse wave velocity
Tsunenori Saito1, Tsunehiro Saito, Shigeyuki Sugiyama
1Department of Cardiology, Nippon Medical School, Tokyo, Japan. tnsaito@good-sleep.gr.jp
Abstract:
Continuous positive airway pressure (CPAP) treatment improves endothelial function and sympathetic activity in patients with obstructive sleep apnea (OSA). However, the long-term effects of CPAP on pulse wave velocity (PWV), which reflects arterial stiffness that is associated with cardiovascular events, have not been evaluated in OSA patients with or without hypertension (HT). In this study, 212 male OSA patients who had been receiving CPAP treatment for 2 years and were divided into two groups, those with HT (n=114) and those without (n=98), were studied. In both HT and normotensive (NT) patients, PWV decreased significantly over the first 6 months of treatment (P=0.005 and 0.010, respectively), before increasing gradually from 6 to 24 months. Body mass index (BMI), body weight, heart rate (HR), systolic blood pressure (SBP) and diastolic blood pressure (DBP) levels decreased significantly in the HT group over the 2 years of CPAP treatment (P<0.001 for all). In contrast, only HR decreased significantly in the NT group over the 2 years of treatment (P<0.001). Multivariate regression analysis revealed that age (P=0.008), decreases in DBP (P<0.001) and HR (P<0.001) and higher initial levels of serum high-density lipoprotein-cholesterol (P=0.040) were independent factors related to changes in PWV over the 2 years of CPAP treatment in all patients. In conclusion, we found a significant decrease in PWV in both NT and HT patients after 6 months of CPAP treatment. In HT patients, long-term CPAP treatment significantly decreases blood pressure, which may contribute to explain the PWV improvement.
Related Concept Videos
Sleep Apnea
The condition is more prevalent among...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Special considerations while measuring pulse
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Measurement of Blood Pressure
